Healthcare provider profile · identity verified

Christopher George Mccarty, DO

Family Practice · EAST EARL, PA · NPI 1336430198

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	251	74
Lisinopril	Lisinopril	248	72
Amlodipine Besylate	Amlodipine Besylate	242	71
Atorvastatin Calcium	Atorvastatin Calcium	241	74
Losartan Potassium	Losartan Potassium	221	62
Hydrochlorothiazide	Hydrochlorothiazide	208	60
Metformin Hcl	Metformin Hcl	173	48
Omeprazole	Omeprazole	166	51
Metoprolol Succinate	Metoprolol Succinate	144	41
Gabapentin	Gabapentin	137	44
Simvastatin	Simvastatin	135	43
Furosemide	Furosemide	109	33
Rosuvastatin Calcium	Rosuvastatin Calcium	108	34
Tramadol Hcl	Tramadol Hcl	108	23
Escitalopram Oxalate	Escitalopram Oxalate	101	30
Pantoprazole Sodium	Pantoprazole Sodium	78	21
Tamsulosin Hcl	Tamsulosin Hcl	77	25
Trulicity	Dulaglutide	77	15
Prednisone	Prednisone	76	54
Clopidogrel	Clopidogrel Bisulfate	73	17
Sertraline Hcl	Sertraline Hcl	71	21
Bupropion Xl	Bupropion Hcl	64	16
Lorazepam	Lorazepam	62	14
Famotidine	Famotidine	59	20
Xarelto	Rivaroxaban	59	14
Synthroid	Levothyroxine Sodium	56	13
Diclofenac Sodium	Diclofenac Sodium	55	26
Metoprolol Tartrate	Metoprolol Tartrate	55	20
Montelukast Sodium	Montelukast Sodium	55	14
Eliquis	Apixaban	54	19
Azithromycin	Azithromycin	53	46
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	53	14
Potassium Chloride	Potassium Chloride	53	15
Alendronate Sodium	Alendronate Sodium	52	16
Amitriptyline Hcl	Amitriptyline Hcl	51	12
Carvedilol	Carvedilol	51	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	47	16
Albuterol Sulfate Hfa	Albuterol Sulfate	46	26
Zolpidem Tartrate	Zolpidem Tartrate	46	13
Glimepiride	Glimepiride	44	11
Triamcinolone Acetonide	Triamcinolone Acetonide	44	26
Duloxetine Hcl	Duloxetine Hcl	43	suppressed
Trazodone Hcl	Trazodone Hcl	43	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	41	suppressed
Pravastatin Sodium	Pravastatin Sodium	39	suppressed
Metformin Hcl Er	Metformin Hcl	38	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	37	17
Atenolol	Atenolol	36	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Fluticasone Propionate	Fluticasone Propionate	36	17
Glipizide	Glipizide	35	11
Ibandronate Sodium	Ibandronate Sodium	34	suppressed
Celecoxib	Celecoxib	32	12
Jardiance	Empagliflozin	32	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	30	25
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	30	suppressed
Finasteride	Finasteride	28	suppressed
Pregabalin	Pregabalin	27	suppressed
Meloxicam	Meloxicam	26	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Azelastine Hcl	Azelastine Hcl	25	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Myrbetriq	Mirabegron	25	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	25	suppressed
Glipizide Er	Glipizide	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	suppressed
Ozempic	Semaglutide	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Warfarin Sodium	Warfarin Sodium	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	20	suppressed
Cephalexin	Cephalexin	20	18
Novolog Flexpen	Insulin Aspart	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Valsartan	Valsartan	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Methylprednisolone	Methylprednisolone	16	16
Allopurinol	Allopurinol	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Nabumetone	Nabumetone	15	suppressed
Naproxen	Naproxen	15	suppressed
Tresiba Flextouch U-200	Insulin Degludec	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Cefuroxime	Cefuroxime Axetil	14	12
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Primidone	Primidone	13	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	11
Eletriptan Hbr	Eletriptan Hydrobromide	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Testosterone	Testosterone	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Carbamazepine	Carbamazepine	11	suppressed
Dexilant	Dexlansoprazole	11	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Lyrica	Pregabalin	11	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error